Literature DB >> 7850462

Effects of dihydrexidine, a full dopamine D-1 receptor agonist, on delayed response performance in chronic low dose MPTP-treated monkeys.

J S Schneider1, Z Q Sun, D P Roeltgen.   

Abstract

Monkeys exposed to low doses of the neurotoxin 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) over long periods of time develop cognitive deficits without severe parkinsonian motor signs. In the present study we assessed the effects of the selective and full dopamine D-1 receptor agonist dihydrexidine on delayed response deficits in chronic low dose (CLD) MPTP-treated monkeys. Dihydrexidine caused a dose-dependent improvement in task performance, that could be blocked by the D-1 receptor antagonist SCH-23390. In addition to reducing the number of mistakes made during delayed response performance, dihydrexidine also improved task persistence. These data suggest that dihydrexidine may be useful in treating cognitive as well as motor deficits of parkinsonism.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7850462     DOI: 10.1016/0006-8993(94)90471-5

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  19 in total

Review 1.  The lesion of the rat substantia nigra pars compacta dopaminergic neurons as a model for Parkinson's disease memory disabilities.

Authors:  Claudio Da Cunha; Miriam Elizabeth Mendes Angelucci; Newton S Canteras; Susan Wonnacott; Reinaldo N Takahashi
Journal:  Cell Mol Neurobiol       Date:  2002-06       Impact factor: 5.046

2.  D1 dopamine receptors intrinsic activity and functional selectivity affect working memory in prefrontal cortex.

Authors:  Yang Yang; Sang-Min Lee; Fumiaki Imamura; Krishne Gowda; Shantu Amin; Richard B Mailman
Journal:  Mol Psychiatry       Date:  2018-12-07       Impact factor: 15.992

3.  SKF-83959 is not a highly-biased functionally selective D1 dopamine receptor ligand with activity at phospholipase C.

Authors:  Sang-Min Lee; Andrew Kant; Daniel Blake; Vishakantha Murthy; Kevin Boyd; Steven J Wyrick; Richard B Mailman
Journal:  Neuropharmacology       Date:  2014-06-12       Impact factor: 5.250

4.  Characterization of in vivo pharmacokinetic properties of the dopamine D1 receptor agonist DAR-0100A in nonhuman primates using PET with [11C] NNC112 and [11C] raclopride.

Authors:  Mark Slifstein; Raymond F Suckow; Jonathan A Javitch; Thomas Cooper; Jeffrey Lieberman; Anissa Abi-Dargham
Journal:  J Cereb Blood Flow Metab       Date:  2010-06-23       Impact factor: 6.200

5.  Identification of RanBP 9/10 as interacting partners for protein kinase C (PKC) gamma/delta and the D1 dopamine receptor: regulation of PKC-mediated receptor phosphorylation.

Authors:  Elizabeth B Rex; Michele L Rankin; Yu Yang; Quansheng Lu; Charles R Gerfen; Pedro A Jose; David R Sibley
Journal:  Mol Pharmacol       Date:  2010-04-15       Impact factor: 4.436

Review 6.  Non-motor features of Parkinson disease.

Authors:  Anthony H V Schapira; K Ray Chaudhuri; Peter Jenner
Journal:  Nat Rev Neurosci       Date:  2017-06-08       Impact factor: 34.870

7.  Characterization of PF-6142, a Novel, Non-Catecholamine Dopamine Receptor D1 Agonist, in Murine and Nonhuman Primate Models of Dopaminergic Activation.

Authors:  Rouba Kozak; Tamás Kiss; Keith Dlugolenski; David E Johnson; Roxanne R Gorczyca; Kyle Kuszpit; Brian D Harvey; Polina Stolyar; Stacey J Sukoff Rizzo; William E Hoffmann; Dmitri Volfson; Mihaly Hajós; Jennifer E Davoren; Amanda L Abbott; Graham V Williams; Stacy A Castner; David L Gray
Journal:  Front Pharmacol       Date:  2020-07-07       Impact factor: 5.810

Review 8.  Targeting the dopamine D1 receptor in schizophrenia: insights for cognitive dysfunction.

Authors:  Patricia S Goldman-Rakic; Stacy A Castner; Torgny H Svensson; Larry J Siever; Graham V Williams
Journal:  Psychopharmacology (Berl)       Date:  2004-04-30       Impact factor: 4.530

Review 9.  Dopamine D1 receptor signaling: does GαQ-phospholipase C actually play a role?

Authors:  Sang-Min Lee; Yang Yang; Richard B Mailman
Journal:  J Pharmacol Exp Ther       Date:  2014-07-22       Impact factor: 4.030

Review 10.  Dopamine receptor signaling and current and future antipsychotic drugs.

Authors:  Kevin N Boyd; Richard B Mailman
Journal:  Handb Exp Pharmacol       Date:  2012
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.